Matt Devalaraja

565 total citations
6 papers, 393 citations indexed

About

Matt Devalaraja is a scholar working on Molecular Biology, Oncology and Immunology. According to data from OpenAlex, Matt Devalaraja has authored 6 papers receiving a total of 393 indexed citations (citations by other indexed papers that have themselves been cited), including 2 papers in Molecular Biology, 2 papers in Oncology and 2 papers in Immunology. Recurrent topics in Matt Devalaraja's work include Immunotherapy and Immune Responses (2 papers), Bacillus and Francisella bacterial research (1 paper) and Hepatitis C virus research (1 paper). Matt Devalaraja is often cited by papers focused on Immunotherapy and Immune Responses (2 papers), Bacillus and Francisella bacterial research (1 paper) and Hepatitis C virus research (1 paper). Matt Devalaraja collaborates with scholars based in United States, Netherlands and Austria. Matt Devalaraja's co-authors include Dean W. Ballard, Ann Richmond, Andrew Chen, Jason Mott, Thi-Sau Migone, Maggie Lewis, John Zhong, Daniel Sanford, Larry Lo and G. Mani Subramanian and has published in prestigious journals such as New England Journal of Medicine, Circulation and Trends in Pharmacological Sciences.

In The Last Decade

Matt Devalaraja

6 papers receiving 378 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Matt Devalaraja United States	5	206	141	99	59	56	6	393
Takaomi Sekino Japan	11	234 1.1×	196 1.4×	93 0.9×	95 1.6×	39 0.7×	16	550
Toyo Suzuki Japan	13	234 1.1×	247 1.8×	108 1.1×	91 1.5×	43 0.8×	17	615
Aws Abdul‐Wahid Canada	14	187 0.9×	151 1.1×	109 1.1×	73 1.2×	19 0.3×	17	447
Isis Torréns Cuba	11	225 1.1×	147 1.0×	45 0.5×	20 0.3×	31 0.6×	21	377
L M Miles United States	7	207 1.0×	114 0.8×	119 1.2×	77 1.3×	72 1.3×	7	387
Koen Oosterhuis Netherlands	13	223 1.1×	265 1.9×	94 0.9×	36 0.6×	63 1.1×	19	482
Yves Poitevin Switzerland	9	199 1.0×	82 0.6×	111 1.1×	21 0.4×	187 3.3×	16	355
Douglas A. Dedera United States	12	419 2.0×	142 1.0×	121 1.2×	136 2.3×	60 1.1×	14	776
Marta Gorraiz Spain	15	120 0.6×	287 2.0×	155 1.6×	27 0.5×	53 0.9×	23	510
Irina Mirkina Austria	16	191 0.9×	308 2.2×	59 0.6×	45 0.8×	21 0.4×	26	590

Countries citing papers authored by Matt Devalaraja

Since Specialization

Citations

This map shows the geographic impact of Matt Devalaraja's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Matt Devalaraja with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Matt Devalaraja more than expected).

Fields of papers citing papers by Matt Devalaraja

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Matt Devalaraja. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Matt Devalaraja. The network helps show where Matt Devalaraja may publish in the future.

Co-authorship network of co-authors of Matt Devalaraja

This figure shows the co-authorship network connecting the top 25 collaborators of Matt Devalaraja. A scholar is included among the top collaborators of Matt Devalaraja based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Matt Devalaraja. Matt Devalaraja is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

6 of 6 papers shown

1.

Kakkar, Rahul, Larry Lo, Douglas Kling, Matt Devalaraja, & Michael H. Davidson. (2019). Abstract 13727: Effects of Ziltivekimab (ZILTI), a Novel Anti-Interleukin-6 Monoclonal Antibody, on Markers of Inflammation and Cardiovascular Risk in Patients With Chronic Kidney Disease on Hemodialysis. Circulation. 3 indexed citations

2.

Jagessar, S. Anwar, Nicole Heijmans, Jan Bauer, et al.. (2012). Antibodies Against Human BLyS and APRIL Attenuate EAE Development in Marmoset Monkeys. Journal of Neuroimmune Pharmacology. 7(3). 557–570. 34 indexed citations

3.

Riggs, Matthew M., James A. Rogers, Marc R. Gastonguay, et al.. (2011). Population Pharmacokinetics and Exposure‐Response of Albinterferon Alfa‐2b. The Journal of Clinical Pharmacology. 52(4). 475–486. 5 indexed citations

4.

Migone, Thi-Sau, G. Mani Subramanian, John Zhong, et al.. (2009). Raxibacumab for the Treatment of Inhalational Anthrax. New England Journal of Medicine. 361(2). 135–144. 202 indexed citations

5.

Devalaraja, Matt, et al.. (1999). Elevated constitutive IkappaB kinase activity and IkappaB-alpha phosphorylation in Hs294T melanoma cells lead to increased basal MGSA/GRO-alpha transcription.. PubMed. 59(6). 1372–7. 78 indexed citations

6.

Devalaraja, Matt. (1999). Multiple chemotactic factors: fine control or redundancy?. Trends in Pharmacological Sciences. 20(4). 151–156. 71 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact